Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alpha-n3
- Development stage
- Unknown
- Lead developer
- AIM ImmunoTech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Interferon alpha-n3 is a natural human interferon alpha product consisting of a multispecies mixture of interferon subtypes derived from human leukocytes. Nobel Pharmaceuticals, in collaboration with Hemispherx Biopharma (now AIM ImmunoTech), developed a low-dose oral lozenge formulation (LDO-IFN-alpha) specifically for the treatment of oral ulcers associated with Behçet's disease. The drug acts as an agonist at the type I interferon receptor (IFNAR), triggering the JAK-STAT signaling pathway to exert immunomodulatory, anti-inflammatory, and antiviral effects. In the context of Behçet's disease, this formulation is intended to reduce the frequency and severity of painful aphthous ulcers by modulating the localized immune response. Clinical development reached Phase II in Turkey, where randomized, double-blind, placebo-controlled studies were conducted to evaluate its safety and efficacy.
- Brand names
- Alferon LDOAlferon N
- Other names
- natural human interferon alphalow dose oral interferon alphainterferon alpha-n3 lozenge
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on interferon alpha-n3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alpha-n3.